DAY 2 - Monday, June 27, 2011
Greetings from the American Diabetes Association’s 71st Scientific Sessions
The editorial staff of Medical Economics brings you daily
coverage of breaking news, the latest research findings, and reports of interest to the
readers of Medical Economics, Drug Topics, Formulary, and Contemporary OB/GYN.
Our four-day coverage of this year’s American Diabetes Association’s 71st Scientific Sessions includes the results of major clinical trials and ongoing news
and information of interest to clinicians who treat type 1 and 2 diabetes.
|
|
BREAKING NEWS
Artificial pancreas passes first test in patients with type 1 diabetes
The first evaluation of a fully automated artificial pancreas in 10 patients shows that the system can safely regulate glycemia in patients with type 1 diabetes even following a meal challenge, without prior meal information, said Howard Zisser, MD.» MORE
|
|
CLINICAL TRIALS
Insulin degludec comparable to glargine in type 1 and 2 DM
Insulin degludec, an ultra-long-acting basal insulin, was not inferior to insulin glargine in 2 separate phase III trials in patients with type 1 or type 2 diabetes.» MORE
|
|
Linagliptin cardiovascular safety profile appears superior to glimepiride
Baptist Gallwitz, MD |
Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.
» MORE
|
|
NEW RESEARCH
TZDs, GLP-1 agonist may worsen diabetic retinal disease
Iskandar Idris, MD |
| |
Lakshminarayanan Varadhan, MD |
Two classes of drugs commonly used to treat type 2 diabetes and theoretically prevent its complications may instead be associated with progression of diabetic retinal disease, said investigators in two studies presented here. Thiazolidinediones (TZDs) are associated with a 3- to 6-fold increase in risk for diabetic macular edema (DME), reported investigators who reviewed a decade of data on more than 100,000 people with type 2 diabetes.
» MORE
|
|
Less hypoglycemia with DPP-4 inhibitor added to metformin than with sulfonylurea
Saxagliptin as an add-on to metformin in patients with type 2 diabetes was associated with fewer episodes of hypoglycemia than add-on glipizide in a randomized, double-blind study.» MORE
|
|
PATIENT MANAGEMENT
Treatment satisfaction for type 2 diabetes patients taking only oral meds
Richard R Rubin, MD |
Patients with type 2 diabetes who use only oral antidiabetic drugs report a more favorable medication treatment experience than those taking insulin, said Richard R Rubin, MD.» MORE |
|
New review confirms safety of metformin in patients with heart failure
Metformin-based strategies for glycemic control are safer than other antihyperglycemic strategies in patients with diabetes and heart failure, according to an update of a systematic review.» MORE
|
|
Retinal thickness predicts nephropathy in long-duration diabetes
Jennifer K Sun, MD, MPH |
Retinal thickness measured by optical coherence tomography (OCT) may be a quantitative, noninvasive method for staging diabetic nephropathy and could serve as a biomarker for worsening disease, said investigators who followed a cohort of patients with long-duration type 1 diabetes.
» MORE |
Medical Economics is pleased to share this ADA conference coverage with the readers of:
 |
|
From the conference floor
|
DISCLAIMER:
This information has been independently developed and provided by the editors of Medical Economics. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
|
|
Exhibit Hall Hours
Monday, June 27
10 a.m. – 2 p.m.
We welcome your feedback!
Please send your comments to:
Medical Economics editorial staff
[email protected] |
|
